SOLO-1 Paves Path for Frontline Maintenance in Ovarian Cancer
Published: Thursday, Aug 01, 2019
Hye Sook Chon, MD
The phase III SOLO-1 trial led to olaparib (Lynparza) becoming the first PARP inhibitor to receive regulatory approval as frontline maintenance treatment in ovarian cancer, marking one of the key advances within this paradigm over the last decade, explained Hye Sook Chon, MD.
... to read the full story